renal-cell carcinoma (advanced)

     

Select            
Trial Studied trt Control trt patientstagsROB Trial resultprogression or death (progression free survival PFS) death (overall survival)

angiogenesis inhibitors

bevacizumab
CALGB 90206, 2010         bevacizumab plus interferon alfainterferon alphasuggesting-29%-14%
AVOREN, 2007         bevacizumab plus interferon alfainterferon alphasuggesting-37%-14%
Yang, 2003       bevacizumabplaceboExploratory -

immune checkpoint inhibition

nivolumab
Chekmate 025 (Motzer), 2015      NCTnivolumabeverolimus2LRisk of bias suggesting-12%-27%
CheckMate-214, 2017      NCTnivolumab + ipilimumabsunitinib1LRisk of bias conclusive-18%-32%

mTOR inhibitor

everolimus
RECORD-1, 2008      NCTeverolimusplacebosuggesting-70%-17%
RECORD 3, 2014      NCTeverolimussunitinib - 40%
temsirolimus
ARCC (Hudes) temsirolimus alone, 2007      NCTtemsirolimusinterferon alphasuggesting-27%
INTORSECT, 2014      NCTtemsirolimussorafenibnegative -13%31%

multi target TKI

not classified
Disruptor-1   BNC105P + everolimuseverolimus -
apitolisib
Powles, 2014   apitolisibeverolimus -
axitinib
AXIS (Rini), 2011      NCTaxitinibsorafenibsuggesting-34%
Qin, 2012   axitinibsorafenib -
cabozantinib
METEOR, 2015    NCTcabozantinibeverolimus after VEGFR-targeted therapy failure 2nd line Risk of bias suggesting-42%-33%
CABOSUN, 2017      NCTcabozantinibsunitinibfirst-line therapy in patients with intermediate- or poor-risk 1st line Exploratory suggesting-34%
dovitinib
GOLD      NCTdovitinibsorafenibRisk of bias negative-14%
pazopanib
Sternberg, 2010     pazopanibplaceboLow risk of bias suggesting-54%
VEG105192, 2010        NCTpazopanibplacebosuggesting-54%-9%
COMPARZ, 2013      NCTpazopanibsunitinibnegative5%-9%
sorafenib
Escudier, 2009     sorafenibinterferon alphaExploratory negative-12%
TARGET, 2007          NCTsorafenibplaceboLow risk of bias suggesting-56%-12%
Ratain, 2006     sorafenibplaceboExploratory -
sunitinib
Motzer, 2007          NCTsunitinibinterferon alphasuggesting-58%-18%
SWITCH      NCTsunitinibsorafenib -
tivozanib
TIVO-1, 2013      NCTtivozanibsorafenibsuggesting-20%25%